Belated Good News: Merck Wins Accelerated Approval In Certain Triple Negative Breast Cancers

The Keytruda® juggernaut marches onward, allowing Merck a consistent, exceedingly high revenue franchise, from which to fund partnerships in other worthwhile, high burden arenas, like HIV and COVID-19.

In truth, this news came out earlier this week, but there were sweet surprises last evening, so I’m just getting to it over coffee this morning. Here’s the bit:

. . .The FDA granted accelerated approval to pembrolizumab combined with chemotherapy for treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1. . . .

As ever, Merck is very well positioned — to once again be the world’s most admired company, as the third decade of the 21st Century opens in a few weeks (as it was, in the middle to late decades of the last century).

We remain hopeful, open and smiling here — for a rekindling of that auspicious stature, in relation to the world at large, and specific portions of her precious human cargo. So, onward!

नमस्ते

There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: